Novavax, Inc. (NVAX) |
|
6.021 0.001 (0.02%)
|
03-22 14:40 |
|
Open: |
6.07 |
Pre. Close: |
6.02 |
|
High:
|
6.1607 |
Low:
|
5.9 |
|
Volume:
|
2,283,603 |
Market Cap:
|
519(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 2:19:36 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 9.95 One year: 12 |
| Support: |
Support1: 5.67 Support2: 4.72 |
| Resistance: |
Resistance1: 8.52 Resistance2: 10.27 |
| Pivot: |
6.52  |
| Moving Average: |
MA(5): 6  MA(20): 7.02
MA(100): 12.89 MA(250): 32.07 |
| MACD: |
MACD(12,26): -1.1 Signal(9): -1.1 |
| Stochastic oscillator: |
%K(14,3): 14.1 %D(3): 10.6 |
| RSI: |
RSI(14): 30.9 |
| 52-week: |
High: 82.3 Low: 5.67 |
| Average Vol(K): |
3-Month: 6,741 (K) 10-Days: 6,187 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NVAX ] has closed above bottom band by 30.7%. Bollinger Bands are 62% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
6.37 - 6.39 |
6.39 - 6.42 |
|
Low:
|
5.86 - 5.89 |
5.89 - 5.91 |
|
Close:
|
5.98 - 6.02 |
6.02 - 6.06 |
|
Company Description |
|
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. |
Headline News |
Mon, 20 Mar 2023
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats - Yahoo Finance
Thu, 09 Mar 2023
Premarket Mover: Novavax Inc (NVAX) Down 1.31% - InvestorsObserver
Wed, 08 Mar 2023
Novavax Inc. (NVAX) Stock: A Closer Look at the Moving Averages - The News Heater
Sun, 05 Mar 2023
Time To Worry? Analysts Just Downgraded Their Novavax, Inc. (NASDAQ:NVAX) Outlook - Simply Wall St
Thu, 02 Mar 2023
Novavax Announces Grant of Inducement Awards Pursuant to ... - Novavax Investor Relations
Wed, 01 Mar 2023
Novavax (NVAX) Q4 Earnings & Revenues Miss Estimates, Stock ... - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
85 (M) |
| Shares Float |
78 (M) |
|
% Held by Insiders
|
2 (%) |
|
% Held by Institutions
|
47.2 (%) |
|
Shares Short
|
30,910 (K) |
|
Shares Short P.Month
|
24,470 (K) |
Stock Financials |
|
EPS
|
-7.27 |
|
EPS Est Next Qtl
|
-0.16 |
|
EPS Est This Year
|
-0.63 |
|
EPS Est Next Year
|
-0.56 |
|
Book Value (p.s.)
|
8.84 |
|
Profit Margin (%)
|
-71.6 |
|
Operating Margin (%)
|
-66.4 |
|
Return on Assets (ttm)
|
-31.8 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
310.7 |
|
Gross Profit (p.s.)
|
-16.36 |
|
Sales Per Share
|
21.76 |
|
EBITDA (p.s.)
|
-14.12 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-641 (M) |
|
Levered Free Cash Flow
|
-1,490 (M) |
Stock Valuations |
|
PE Ratio
|
-0.85 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0.69 |
|
Price to Sales
|
0.28 |
|
Price to Cash Flow
|
-0.82 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-05-09 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
